How This Evidence Evolved
Dual Antiplatelet Duration Post-PCI
Finding the sweet spot between ischaemia and bleeding
Timeline
Early observations and pilot data that first suggested a new direction
Landmark RCTs and pivotal trials that established the evidence base
12-month composite: 1-month DAPT 2.36% vs 12-month DAPT 3.70% (superiority P=.04)
BARC 2/3/5 bleeding over 12 months, NSTE-ACS: ticagrelor alone 3.6% vs DAPT 7.6% (HR 0.47, 95% CI 0.36–0.61)
Net adverse clinical events: HR 0.66 (95% CI 0.48–0.92) favouring ticagrelor monotherapy
Follow-up studies, subgroup analyses, and real-world validation
Current standard of care and ongoing research directions
Landmark Trials in This Story
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents
12–30 mo stent thrombosis: long DAPT 0.4% vs aspirin 1.4% (P<.001); moderate/severe bleeding 2.5% vs 1.6%
Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial
12-month composite: 1-month DAPT 2.36% vs 12-month DAPT 3.70% (superiority P=.04)
Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS
BARC 2/3/5 bleeding over 12 months, NSTE-ACS: ticagrelor alone 3.6% vs DAPT 7.6% (HR 0.47, 95% CI 0.36–0.61)
Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial
Net adverse clinical events: HR 0.66 (95% CI 0.48–0.92) favouring ticagrelor monotherapy
Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk
Major/CRNM bleeding at 335 days: abbreviated 6.5% vs standard 9.4% (P<0.001)
Explore the evidence yourself
Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.